利拉鲁肽治疗NAFLD的疗效与安全性系统评价
Systematic evaluation of efficacy and safety of liraglutide in the treatment of NAFLD
任欣欣 1刘嘉 1雷艳 1王芳 1成姝婷 2应俊杰 3杨淑红4
作者信息
- 1. 兰州理工大学生命科学与工程学院,甘肃 兰州 30050
- 2. 四川大学国家卫生健康委员会时间生物学重点实验室,四川 成都 610041
- 3. 四川大学出生缺陷与相关妇儿疾病教育部重点实验室,四川 成都 610041
- 4. 兰州理工大学生命科学与工程学院,甘肃 兰州 30050;四川大学国家卫生健康委员会时间生物学重点实验室,四川 成都 610041;四川大学出生缺陷与相关妇儿疾病教育部重点实验室,四川 成都 610041
- 折叠
摘要
目的:系统评价利拉鲁肽治疗NAFLD的疗效和安全性.方法:检索和筛选中外文文献数据库的相关文献进行meta分析.结果:共纳入 15 篇文献,共 924 例患者.结果显示利拉鲁肽不能有效提高NAFLD的治愈率.与对照组相比,经利拉鲁肽治疗后,NAFLD患者肝脂肪含量、肝纤维化评分和血清ALT水平明显下降,具有统计学意义;血清AST和γ-GGT的变化与对照组无明显差异.胃肠道不良反应的发生率在利拉鲁肽和对照组之间无统计学差异.结论:利拉鲁肽能够降低NAFLD患者的肝脏脂肪含量,改善肝纤维化水平,且患者对利拉鲁肽的胃肠道不良反应有较好的耐受性.
Abstract
Objective:To assess the efficacy and safety of liraglutide for treatment of NAFLD.Methods:Relevant literature in Chinese and foreign language literature databases were searched and screened for meta-analysis.Results:A total of 15 studies including 924 patients were included.Mata analysis showed that there was no significant difference in NAFLD resolution rate between liraglutide and control group.Compared to control group,treatment with liraglutide was significantly associated with decrease in liver fat content,liver fibrosis scores and serum ALT.Serum AST and γ-GGT were not significantly improved in liraglutide group when compared with the control group.Furthermore,there was no significant correlation of occurrence rate of adverse events(nausea,vomiting and diarrhea)with liraglutide.Conclusions:Liraglutide treatment can reduce liver fat content,improve liver fibrosis in NAFLD patients,and the gastrointestinal adverse effects of liraglutide are well tolerated in patients.
关键词
利拉鲁肽/肝脏脂肪含量/肝纤维化/肝酶/非酒精性脂肪肝病Key words
Liraglutide/Liver fat content/Liver fibrosis/Liver enzymes/Non-alcoholic fatty liver disease引用本文复制引用
基金项目
四川大学NHC时间生物学重点实验室开放基金(NHCC-2022-03)
四川省妇幼重点实验室发育与相关疾病基金(SCU2022D006)
出版年
2024
NETL
NSTL
维普
万方数据